Update: 14.03.2021
Last week: 9 week 2022 (28.02.2022 - 6.03.2022)
Last full month: Feb 2021
9я неделя (с 28.02 по 06.03) стала стрессовой для многих категорий
Очевидные причины – закупка впрок на фоне валютных скачков и возможных логистических проблем
В качестве бенчмарка – рост продаж инсулина (Новорапид - +213% WoW, Лантус - +316% WoW) По брендам Grindex следующая ситуация:
МИЛДРОНАТ
Прирост продаж в упаковках (Week-over-Week) на 59,8%
Ускорилась уходимость новых SKU по новым ценам - #20 250mg и #60 500 mg - до 1,5-2 тыс за неделю. Скачкообразный рост спроса и вымывания по старым ценам ускоряет «расправление плеч» новых sku
ВИПРОСАЛ
Рост продаж в упаковках (Week-over-Week) на 56,2%
Немного быстрее, чем категория в целом – это хороший знак силы обновленного бренда Пока не исследовали вопрос дефектуры, но в целом на этих значениях роста – это скорее локальное вымывание в отдельных аптеках
КАПСИКАМ
Рост продаж в упаковках (Week-over-Week) на 25,4% Темпы роста в 2 раза ниже категории – нужно разбираться в причинах. Одна из скрытых и неочевидных на первый взгляд – меньший процент регулярных «хронических» потребителей, которые пополняют запасы загодя
СУЛЬФАРГИН
Рост продаж в упаковках (Week-over-Week) на 21,8%
Значимо ниже прироста категории – вероятнее всего потребители делали фокус на закупках дорогих западных препаратов
Очевидно, что дефектура, как в случае и с Капсикамом – минимальна
АПИЛАК
Рост продаж в упаковках (Week-over-Week) на 24,7%
Неделя без больших аномалий. По сути, за 7 дней продали столько, сколько должны были продавать за 9
У всех брендов прирост выше по большим упаковкам, прирост средней цены практически по всем SKU - на 10-20% (скорее всего потому, что просто покупали везде, в том числе в дорогих аптеках)
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | |||||||||
| WoW | 3 592 | 24.7% | 58.4% | -0.2 | 1 672 573 | 29.5% | 84.3% | 0 | 25.1% |
| MoM | 11 577 | 16.9% | 55.7% | 4.2 | 5 204 099 | 19.8% | 82.7% | 2.8 | 8.1% |
| YTD | 24 266 | 5.1% | 54.5% | -4.2 | 10 854 223 | 32.9% | 81.9% | 0.6 | 13.2% |
| MAT | 118 787 | -21.7% | 54.8% | -6.7 | 48 298 627 | 3.6% | 80.4% | -0.7 | -12.1% |
| CAPSICAM | |||||||||
| WoW | 27 570 | 25.4% | 3.0% | -0.7 | 11 779 407 | 30.1% | 2.7% | -1 | 54.9% |
| MoM | 184 740 | -6.2% | 3.7% | -0.2 | 75 707 986 | -6.3% | 3.8% | -0.3 | -1.2% |
| YTD | 208 565 | -9.4% | 3.6% | -0.3 | 85 909 077 | -11.5% | 3.7% | -0.9 | -2.0% |
| MAT | 1 043 422 | -20.6% | 3.3% | -0.4 | 427 829 990 | -12.8% | 3.6% | -0.5 | -11.1% |
| MILDRONATE | |||||||||
| WoW | 202 142 | 59.8% | 23.2% | 0.7 | 117 534 769 | 87.1% | 22.7% | 1 | 54.9% |
| MoM | 507 422 | 17.9% | 21.8% | 1 | 242 156 427 | 38.3% | 20.6% | 2.7 | 12.5% |
| YTD | 1 090 192 | 25.6% | 16.6% | 1.8 | 509 976 818 | 37.6% | 16.2% | 2 | 12.0% |
| MAT | 5 018 000 | 11.4% | 16.8% | 2.6 | 2 072 772 436 | 16.3% | 15.0% | 2.1 | -5.9% |
| SULFARGIN | |||||||||
| WoW | 4 086 | 21.8% | 0.7% | -0.2 | 2 044 022 | 25.6% | 0.9% | -0.4 | 54.8% |
| MoM | 14 059 | 2.0% | 1.0% | 0 | 6 756 585 | 0.2% | 1.3% | 0 | 2.0% |
| YTD | 30 407 | 5.2% | 0.9% | 0.1 | 14 800 201 | 9.7% | 1.3% | 0.2 | -6.3% |
| MAT | 165 661 | -20.2% | 0.8% | -0.1 | 81 066 416 | -8.7% | 1.2% | 0 | -10.8% |
| VIPROSAL | |||||||||
| WoW | 43 906 | 56.2% | 4.4% | 0.1 | 18 719 558 | 67.6% | 4.1% | -0.3 | 52.7% |
| MoM | 122 479 | 0.5% | 4.5% | 0.1 | 48 514 619 | 1.0% | 4.5% | 0 | -1.7% |
| YTD | 274 751 | 37.0% | 4.4% | 1.2 | 109 688 881 | 41.4% | 4.4% | 1 | -0.1% |
| MAT | 1 317 726 | -4.6% | 3.9% | 0.3 | 503 366 451 | 2.8% | 3.9% | 0.1 | -11.9% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 3 592 | 24.7% | 58.4% | -0.2 | 1 672 573 | 29.5% | 84.3% | 0 | 25.1% |
| KAPSIKAM | 27 570 | 25.4% | 3.0% | -0.7 | 11 779 407 | 30.1% | 2.7% | -1 | 54.9% |
| MILDRONATE | 202 142 | 59.8% | 23.2% | 0.7 | 117 534 769 | 87.1% | 22.7% | 1 | 54.9% |
| SULFARGIN | 4 086 | 21.8% | 0.7% | -0.2 | 2 044 022 | 25.6% | 0.9% | -0.4 | 54.8% |
| VIPROSAL | 43 906 | 56.2% | 4.4% | 0.1 | 18 719 558 | 67.6% | 4.1% | -0.3 | 52.7% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 11 577 | 16.9% | 55.7% | 4.2 | 5 204 099 | 19.8% | 82.7% | 2.8 | 8.1% |
| KAPSIKAM | 184 740 | -6.2% | 3.7% | -0.2 | 75 707 986 | -6.3% | 3.8% | -0.3 | -1.2% |
| MILDRONATE | 507 422 | 17.9% | 21.8% | 1 | 242 156 427 | 38.3% | 20.6% | 2.7 | 12.5% |
| SULFARGIN | 14 059 | 2.0% | 1.0% | 0 | 6 756 585 | 0.2% | 1.3% | 0 | 2.0% |
| VIPROSAL | 122 479 | 0.5% | 4.5% | 0.1 | 48 514 619 | 1.0% | 4.5% | 0 | -1.7% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 24 266 | 5.1% | 54.5% | -4.2 | 10 854 223 | 32.9% | 81.9% | 0.6 | 13.2% |
| KAPSIKAM | 208 565 | -9.4% | 3.6% | -0.3 | 85 909 077 | -11.5% | 3.7% | -0.9 | -2.0% |
| MILDRONATE | 1 090 192 | 25.6% | 16.6% | 1.8 | 509 976 818 | 37.6% | 16.2% | 2 | 12.0% |
| SULFARGIN | 30 407 | 5.2% | 0.9% | 0.1 | 14 800 201 | 9.7% | 1.3% | 0.2 | -6.3% |
| VIPROSAL | 274 751 | 37.0% | 4.4% | 1.2 | 109 688 881 | 41.4% | 4.4% | 1 | -0.1% |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. | Cat.Vol, Change |
|---|---|---|---|---|---|---|---|---|---|
| APILAC | 118 787 | -21.7% | 54.8% | -6.7 | 48 298 627 | 3.6% | 80.4% | -0.7 | -12.1% |
| KAPSIKAM | 1 043 422 | -20.6% | 3.3% | -0.4 | 427 829 990 | -12.8% | 3.6% | -0.5 | -11.1% |
| MILDRONATE | 5 018 000 | 11.4% | 16.8% | 2.6 | 2 072 772 436 | 16.3% | 15.0% | 2.1 | -5.9% |
| SULFARGIN | 165 661 | -20.2% | 0.8% | -0.1 | 81 066 416 | -8.7% | 1.2% | 0 | -10.8% |
| VIPROSAL | 1 317 726 | -4.6% | 3.9% | 0.3 | 503 366 451 | 2.8% | 3.9% | 0.1 | -11.9% |
## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "KAPSIKAM"## [1] "KAPSIKAM UNGUENT FOR EXT USE 30 G #1"## [1] "KAPSIKAM UNGUENT FOR EXT USE 50 G #1"## [1] "KAPSIKAM"## [1] "KAPSIKAM UNGUENT FOR EXT USE 30 G #1"## [1] "KAPSIKAM UNGUENT FOR EXT USE 50 G #1"## [1] "MILDRONATE CAPS 500 MG #30"## [1] "MILDRONATE CAPS 250 MG #20"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #30"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "MILDRONATE CAPS 500 MG #30"## [1] "MILDRONATE CAPS 250 MG #20"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #30"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs